Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CASI Pharmaceuticals, Inc. - Ordinary Shares (NQ:CASI)

0.3081 -0.4919 (-61.49%)
Streaming Delayed Price Updated: 1:59 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,187,471
Open 0.3400
Bid (Size) 0.3080 (2,500)
Ask (Size) 0.3081 (300)
Prev. Close 0.8000
Today's Range 0.2500 - 0.3749
52wk Range 0.7400 - 3.090
Shares Outstanding 13,378,175
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? ↗
CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market. 
Via Stocktwits
News headline image
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
Via ACCESS Newswire

Performance

YTD
-62.6%
-62.6%
1 Month
-68.6%
-68.6%
3 Month
-72.7%
-72.7%
6 Month
-86.5%
-86.5%
1 Year
-87.3%
-87.3%

More News

Read More
News headline image
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Changes in Board Governance
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
CASI Pharmaceuticals Appoints James Huang to Board of Directors
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
Via ACCESS Newswire
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is CASI Pharmaceuticals, Inc. - Ordinary Shares publicly traded?
Yes, CASI Pharmaceuticals, Inc. - Ordinary Shares is publicly traded.
What exchange does CASI Pharmaceuticals, Inc. - Ordinary Shares trade on?
CASI Pharmaceuticals, Inc. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CASI Pharmaceuticals, Inc. - Ordinary Shares?
The ticker symbol for CASI Pharmaceuticals, Inc. - Ordinary Shares is CASI on the Nasdaq Stock Market
What is the current price of CASI Pharmaceuticals, Inc. - Ordinary Shares?
The current price of CASI Pharmaceuticals, Inc. - Ordinary Shares is 0.3081
When was CASI Pharmaceuticals, Inc. - Ordinary Shares last traded?
The last trade of CASI Pharmaceuticals, Inc. - Ordinary Shares was at 02/25/26 01:59 PM ET
What is the market capitalization of CASI Pharmaceuticals, Inc. - Ordinary Shares?
The market capitalization of CASI Pharmaceuticals, Inc. - Ordinary Shares is 4.12M
How many shares of CASI Pharmaceuticals, Inc. - Ordinary Shares are outstanding?
CASI Pharmaceuticals, Inc. - Ordinary Shares has 4M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.